Latterell Venture Partners

Latterell Venture Partners

Latterell Venture Partners

Suggest edits
Follow us
Also headquartered in San Francisco
Terms of Service Privacy Policy Cookie Statement
Built with ❤︎ by Datalicious ©2022
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

News

Investments 13

Portfolio

Portfolio Tracker

Add info
Pulse 2.0

Viracta Therapeutics (VIRX) Stock: Why The Price Jumped Up Today

Viracta Therapeutics
Viracta Therapeutics
The
The
Pulse 2.0

Aptinyx Stock (APTX): Why The Price Increased Today

Aptinyx Inc.
Aptinyx Inc.
The
The
Pulse 2.0

Aptinyx Stock Price Increased Over 4% Pre-Market: Why It Happened

Aptinyx Inc.
Aptinyx Inc.
$66,000,000 Venture capital (Series H)
FinSMEs

Pulmonx Raises $66M in Financing

Pulmonx Corporation
Pulmonx Corporation
Xconomy

Aptinyx Moves Ahead With PTSD Therapy Study, Pauses 3 Other Trials

Aptinyx Inc.
Aptinyx Inc.
FinSMEs

Viracta Therapeutics Closes Series D Financing

Viracta Therapeutics
Viracta Therapeutics
the home of AI info

Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th ...

Aptinyx Inc.
Aptinyx Inc.
$65,000,000 Undisclosed
DealStreetAsia

HK’s Ally Bridge Group leads $65m financing for US-based Pulmonx

Pulmonx Corporation
Pulmonx Corporation
PE HUB

VC-backed Aptinyx goes public

Stock markets Funding
Aptinyx Inc.
Aptinyx Inc.
$70,000,000 Venture capital (Series B)
PE HUB , Venture Funding News

| Aptinyx lands $70 mln Series B

Aptinyx Inc.
Aptinyx Inc.
$18,400,000 Venture capital (Series B)
FierceBiotech

Viracta nabs $18.4M, Soon-Shiong as vice chair in Series B

Viracta Therapeutics
Viracta Therapeutics
$65,000,000 Venture capital (Series A)
biospace , FinSMEs

Naurex Spinout Aptinyx Banks 65 Million Series A to Advance Therapies for Neurological Disorders

Science Funding Health